세계의 간세포 성장인자(HGF) : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)

The global market for Hepatocyte Growth Factor was estimated to be worth US$ 75.8 million in 2024 and is forecast to a readjusted size of US$ 426 million by 2031 with a CAGR of 28.0% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Hepatocyte Growth Factor cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Hepatocyte growth factor (HGF) (or scatter factor (SF) is a paracrine cellular growth, motility and morphogenic factor. It is secreted by mesenchymal cells and targets and acts primarily upon epithelial cells and endothelial cells, but also acts on haemopoietic progenitor cells and T cells. It has been shown to have a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration, and in wound healing.

Current drug development targeting the HGF pathway is bifurcated into neuroregeneration and oncology tracks, with clinical pipelines focused on indications such as diabetic neuropathy, ALS, spinal cord injury, stroke, and various solid tumors including NSCLC and gastric cancer. Globally, companies like Helixmith, AnGes MG, and Kringle Pharma are advancing gene therapies and recombinant proteins for neurological indications. Athira Pharma and AVEO are developing small molecules and antibodies targeting the HGF/c-Met axis, while Exelixis and Molecular Partners pursue broader oncology strategies via multi-target approaches. Beijing Northland represents China's early-stage involvement in this area. The landscape is marked by diversified modalities and parallel development paths, with several assets reaching late-stage trials or conditional approvals, indicating strong commercialization potential in regenerative medicine and rare diseases.

This report aims to provide a comprehensive presentation of the global market for Hepatocyte Growth Factor, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Hepatocyte Growth Factor by region & country, by Type, and by Application.

The Hepatocyte Growth Factor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatocyte Growth Factor.

Market Segmentation

By Company

• Helixsmith
• Exelixis
• AnGes MG
• Athira Pharma
• AVEO Pharmaceuticals
• Molecular Partners
• Kringle Pharma
• Beijing Northland

Segment by Type

• Phase III (Ongoing)
• Phase II (Approved)
• Phase II (Ongoing)
• Phase 1
• Preclinical
• Approved / Marketed

Segment by Application

• Oncology
• Cardiovascular
• Central Nervous System
• Hematological Disorders
• Others

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Hepatocyte Growth Factor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Hepatocyte Growth Factor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Hepatocyte Growth Factor in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Hepatocyte Growth Factor Product Introduction
• 1.2 Global Hepatocyte Growth Factor Market Size Forecast
  • 1.2.1 Global Hepatocyte Growth Factor Sales Value (2020-2031)
  • 1.2.2 Global Hepatocyte Growth Factor Sales Volume (2020-2031)
  • 1.2.3 Global Hepatocyte Growth Factor Sales Price (2020-2031)
• 1.3 Hepatocyte Growth Factor Market Trends & Drivers
  • 1.3.1 Hepatocyte Growth Factor Industry Trends
  • 1.3.2 Hepatocyte Growth Factor Market Drivers & Opportunity
  • 1.3.3 Hepatocyte Growth Factor Market Challenges
  • 1.3.4 Hepatocyte Growth Factor Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Hepatocyte Growth Factor Players Revenue Ranking (2024)
• 2.2 Global Hepatocyte Growth Factor Revenue by Company (2020-2025)
• 2.3 Global Hepatocyte Growth Factor Players Sales Volume Ranking (2024)
• 2.4 Global Hepatocyte Growth Factor Sales Volume by Company Players (2020-2025)
• 2.5 Global Hepatocyte Growth Factor Average Price by Company (2020-2025)
• 2.6 Key Manufacturers Hepatocyte Growth Factor Manufacturing Base and Headquarters
• 2.7 Key Manufacturers Hepatocyte Growth Factor Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of Hepatocyte Growth Factor
• 2.9 Hepatocyte Growth Factor Market Competitive Analysis
  • 2.9.1 Hepatocyte Growth Factor Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by Hepatocyte Growth Factor Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatocyte Growth Factor as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Phase III (Ongoing)
  • 3.1.2 Phase II (Approved)
  • 3.1.3 Phase II (Ongoing)
  • 3.1.4 Phase 1
  • 3.1.5 Preclinical
  • 3.1.6 Approved / Marketed
• 3.2 Global Hepatocyte Growth Factor Sales Value by Type
  • 3.2.1 Global Hepatocyte Growth Factor Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Hepatocyte Growth Factor Sales Value, by Type (2020-2031)
  • 3.2.3 Global Hepatocyte Growth Factor Sales Value, by Type (%) (2020-2031)
• 3.3 Global Hepatocyte Growth Factor Sales Volume by Type
  • 3.3.1 Global Hepatocyte Growth Factor Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global Hepatocyte Growth Factor Sales Volume, by Type (2020-2031)
  • 3.3.3 Global Hepatocyte Growth Factor Sales Volume, by Type (%) (2020-2031)
• 3.4 Global Hepatocyte Growth Factor Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Oncology
  • 4.1.2 Cardiovascular
  • 4.1.3 Central Nervous System
  • 4.1.4 Hematological Disorders
  • 4.1.5 Others
• 4.2 Global Hepatocyte Growth Factor Sales Value by Application
  • 4.2.1 Global Hepatocyte Growth Factor Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Hepatocyte Growth Factor Sales Value, by Application (2020-2031)
  • 4.2.3 Global Hepatocyte Growth Factor Sales Value, by Application (%) (2020-2031)
• 4.3 Global Hepatocyte Growth Factor Sales Volume by Application
  • 4.3.1 Global Hepatocyte Growth Factor Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global Hepatocyte Growth Factor Sales Volume, by Application (2020-2031)
  • 4.3.3 Global Hepatocyte Growth Factor Sales Volume, by Application (%) (2020-2031)
• 4.4 Global Hepatocyte Growth Factor Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global Hepatocyte Growth Factor Sales Value by Region
  • 5.1.1 Global Hepatocyte Growth Factor Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Hepatocyte Growth Factor Sales Value by Region (2020-2025)
  • 5.1.3 Global Hepatocyte Growth Factor Sales Value by Region (2026-2031)
  • 5.1.4 Global Hepatocyte Growth Factor Sales Value by Region (%), (2020-2031)
• 5.2 Global Hepatocyte Growth Factor Sales Volume by Region
  • 5.2.1 Global Hepatocyte Growth Factor Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global Hepatocyte Growth Factor Sales Volume by Region (2020-2025)
  • 5.2.3 Global Hepatocyte Growth Factor Sales Volume by Region (2026-2031)
  • 5.2.4 Global Hepatocyte Growth Factor Sales Volume by Region (%), (2020-2031)
• 5.3 Global Hepatocyte Growth Factor Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America Hepatocyte Growth Factor Sales Value, 2020-2031
  • 5.4.2 North America Hepatocyte Growth Factor Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe Hepatocyte Growth Factor Sales Value, 2020-2031
  • 5.5.2 Europe Hepatocyte Growth Factor Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific Hepatocyte Growth Factor Sales Value, 2020-2031
  • 5.6.2 Asia Pacific Hepatocyte Growth Factor Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America Hepatocyte Growth Factor Sales Value, 2020-2031
  • 5.7.2 South America Hepatocyte Growth Factor Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa Hepatocyte Growth Factor Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa Hepatocyte Growth Factor Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Hepatocyte Growth Factor Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Hepatocyte Growth Factor Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions Hepatocyte Growth Factor Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions Hepatocyte Growth Factor Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States Hepatocyte Growth Factor Sales Value, 2020-2031
  • 6.3.2 United States Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Hepatocyte Growth Factor Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Hepatocyte Growth Factor Sales Value, 2020-2031
  • 6.4.2 Europe Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Hepatocyte Growth Factor Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Hepatocyte Growth Factor Sales Value, 2020-2031
  • 6.5.2 China Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Hepatocyte Growth Factor Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Hepatocyte Growth Factor Sales Value, 2020-2031
  • 6.6.2 Japan Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Hepatocyte Growth Factor Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Hepatocyte Growth Factor Sales Value, 2020-2031
  • 6.7.2 South Korea Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Hepatocyte Growth Factor Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Hepatocyte Growth Factor Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Hepatocyte Growth Factor Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Hepatocyte Growth Factor Sales Value, 2020-2031
  • 6.9.2 India Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Hepatocyte Growth Factor Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Helixsmith
  • 7.1.1 Helixsmith Company Information
  • 7.1.2 Helixsmith Introduction and Business Overview
  • 7.1.3 Helixsmith Hepatocyte Growth Factor Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 Helixsmith Hepatocyte Growth Factor Product Offerings
  • 7.1.5 Helixsmith Recent Development
• 7.2 Exelixis
  • 7.2.1 Exelixis Company Information
  • 7.2.2 Exelixis Introduction and Business Overview
  • 7.2.3 Exelixis Hepatocyte Growth Factor Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 Exelixis Hepatocyte Growth Factor Product Offerings
  • 7.2.5 Exelixis Recent Development
• 7.3 AnGes MG
  • 7.3.1 AnGes MG Company Information
  • 7.3.2 AnGes MG Introduction and Business Overview
  • 7.3.3 AnGes MG Hepatocyte Growth Factor Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 AnGes MG Hepatocyte Growth Factor Product Offerings
  • 7.3.5 AnGes MG Recent Development
• 7.4 Athira Pharma
  • 7.4.1 Athira Pharma Company Information
  • 7.4.2 Athira Pharma Introduction and Business Overview
  • 7.4.3 Athira Pharma Hepatocyte Growth Factor Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 Athira Pharma Hepatocyte Growth Factor Product Offerings
  • 7.4.5 Athira Pharma Recent Development
• 7.5 AVEO Pharmaceuticals
  • 7.5.1 AVEO Pharmaceuticals Company Information
  • 7.5.2 AVEO Pharmaceuticals Introduction and Business Overview
  • 7.5.3 AVEO Pharmaceuticals Hepatocyte Growth Factor Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 AVEO Pharmaceuticals Hepatocyte Growth Factor Product Offerings
  • 7.5.5 AVEO Pharmaceuticals Recent Development
• 7.6 Molecular Partners
  • 7.6.1 Molecular Partners Company Information
  • 7.6.2 Molecular Partners Introduction and Business Overview
  • 7.6.3 Molecular Partners Hepatocyte Growth Factor Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.6.4 Molecular Partners Hepatocyte Growth Factor Product Offerings
  • 7.6.5 Molecular Partners Recent Development
• 7.7 Kringle Pharma
  • 7.7.1 Kringle Pharma Company Information
  • 7.7.2 Kringle Pharma Introduction and Business Overview
  • 7.7.3 Kringle Pharma Hepatocyte Growth Factor Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.7.4 Kringle Pharma Hepatocyte Growth Factor Product Offerings
  • 7.7.5 Kringle Pharma Recent Development
• 7.8 Beijing Northland
  • 7.8.1 Beijing Northland Company Information
  • 7.8.2 Beijing Northland Introduction and Business Overview
  • 7.8.3 Beijing Northland Hepatocyte Growth Factor Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.8.4 Beijing Northland Hepatocyte Growth Factor Product Offerings
  • 7.8.5 Beijing Northland Recent Development

8 Industry Chain Analysis

• 8.1 Hepatocyte Growth Factor Industrial Chain
• 8.2 Hepatocyte Growth Factor Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Hepatocyte Growth Factor Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Hepatocyte Growth Factor Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer